NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

2046.00 -17.20 (-0.83%)

279.9K NSE+BSE Volume

NSE 16 Sep, 2026 10:49 AM (IST)

93,556.6

Market Cap

High in industry

Beta 1Year

Very Low volatility

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Search Inside the pdf :

Lupin Ltd.

10 Aug 2026

2046.00

-0.83%

Expect a muted FY27, launches across geographies will drive the FY28 growth.

Accumulate: Lupin Ltd.

Target

Deven Choksey

Lupin’s next phase of growth and potential re-rating will largely depend on its ability to execute the planned product launches across geographies, particularly in the US.

Lupin Ltd. has an average target of 2492.00 from 9 brokers.

Lupin Ltd.

09 Aug 2026

2046.00

-0.83%

Headwinds in the US to impact growth

Sell: Lupin Ltd.

Recommendation

ICICI Securities Limited

Lupin delivered a strong Q1FY27, led by exclusivities in the US (+29.8%) and robust growth in emerging (+51.7%) and other developed markets (+48.3%).

Lupin Ltd. is trading below all available SMAs

Lupin Ltd.

08 Aug 2026

2046.00

-0.83%

Execution drives another earnings beat

Neutral: Lupin Ltd.

Target

Motilal Oswal

Lupin (LPC) has delivered a better-than-expected financial performance in 1QFY27, with 5%/15% beat on revenue/EBITDA. Compared to the EBITDA beat, the PAT beat was lower because of higher depreciation and tax rate.

Lupin Ltd. has an average target of 2492.00 from 9 brokers.

Lupin Ltd.

06 Aug 2026

2046.00

-0.83%

Lupin Ltd.– Q1FY27 Preview

Hold: Lupin Ltd.

Target

Deven Choksey

Lupin is expected to report Q1 FY27 revenue of INR 78,286 Mn, reflecting a robust 25% YoY growth, driven by continued strength across its key operating markets.

Lupin Ltd. is trading below all available SMAs

Lupin Ltd.

04 Jun 2026

2046.00

-0.83%

LUPIN LIMITED

Buy: Lupin Ltd.

Target

Geojit BNP Paribas

Lupin's strong double-digit growth continues to be driven by robust US market leadership, expanding traction in the respiratory portfolio and deepening complex generics capabilities. Management has guided for sustained revenue growth with stable margins, supported by continued R&D investment. The company's focus on accelerating ANDA filings and building a differentiated 505(b)(2) and biosimilar pipeline are expected to support sustained growth momentum. The strategic push into specialty segments through organic initiatives and targeted acquisitions,...

Number of FII/FPI investors increased from 979 to 999 in Jun 2026 qtr.

Lupin Ltd.

14 May 2026

2046.00

-0.83%

Outlook

Hold: Lupin Ltd.

Recommendation Target

Deven Choksey

The company’s near-term earnings outlook is expected to go through a transition phase rather than maintain strong growth momentum.

Number of FII/FPI investors increased from 979 to 999 in Jun 2026 qtr.

Lupin Ltd.

11 May 2026

2046.00

-0.83%

Lupin (LPC IN) Q4FY26 Result Update Sustainability of US sales will be key ACCUMULATE

Accumulate: Lupin Ltd.

Recommendation Target

Prabhudas Lilladhar

Higher US revenues spur growth YoY: Revenues grew 33% YoY to INR 74bn, vs our estimate INR 69.4bn. Beat was on account of higher US revenues which stood at USD contribution from gTolvaptan, continued flu season and other launches. India formulation grew by 11.5% YoY. EMs increased sharply by 49%, while other developed markets increased by 7% YoY. API business showed recovery up 8% YoY....

Lupin Ltd. is trading below all available SMAs

Lupin Ltd.

10 May 2026

2046.00

-0.83%

Lupin (BUY): On the verge of becoming a USD 1bn EBITDA company by FY29

Buy: Lupin Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/APAT surpassed our 4QFY26 estimates by 8.1%/18.5%/12.7% respectively; EBITDA Margin by 254 bps

Lupin Ltd. is trading below all available SMAs

Lupin Ltd.

10 May 2026

2046.00

-0.83%

Broad-based growth drives earnings; strong finish in FY26

Neutral: Lupin Ltd.

Target

Motilal Oswal

Lupin (LPC) delivered another quarter of strong performance with a 7%/11%/10% beat on revenue/EBITDA/PAT for the quarter.

Number of FII/FPI investors increased from 979 to 999 in Jun 2026 qtr.

Lupin Ltd.

16 Feb 2026, 12:00AM

2046.00

-0.83%

Dependency on US exclusivity rising

Hold: Lupin Ltd.

Target

ICICI Securities Limited

Beat in Q3FY26 vs our expectation was mainly driven by stellar performance in the US region, posting revenue of USD 350mn (up 46.8% YoY). Apart from a few seasonal products, sales in US were largely led by Tolvaptan, Mirabegron and Spiriva.

Lupin Ltd. is trading below all available SMAs

Is Lupin Ltd. worth buying?

946 Votes:

Buy 73.04%

Sell 17.34%

Hold 9.62%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf